Exiqon Diagnostics has begun beta testing on the PortiQo Doctor Portal, which will allow oncologists to connect directly to the company.
The platform offers secure communication though a Web-based portal system that delivers test reports and content directly to oncologists. The system was developed to enhance efficiency, improve quality, and streamline the reporting process, according to Exiqon.
Also, the company has launched a patient registry for colon, lung, and ovarian cancer in conjunction with its ArQive observational study for the Oncotech Extreme Drug Resistance (EDR) Assay. The registry will collect clinical outcome and treatment data from 400 ovarian, 300 colon, and 300 lung cancer patients tested with the assay in order to evaluate drug resistance prior to combination chemotherapy. The registry will correlate the assay results and drug treatment to clinical outcome over a five-year period. MiRNA data will also be collected and used in the development of new diagnostic assays.
